Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, novembre 21
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Dr Reddy's Laboratories Ltd
RDY
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$14.89
0.06
0.4%
In chiusura: Nov 20, 4:00 PM EST
$15.00
0.11
0.74%
Post-mercato: 7:10 PM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Dividendi
Confronta
Rapporto azionario
Dr Reddy's Laboratories Financials
Dr Reddy's Laboratories (RDY) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Dr Reddy's Laboratories Q2 EPS $0.12 Misses $0.16 Estimate, Sales $905.000M Miss $980.650M Estimate
Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.16 by 25 percent. This is a 36.84 percent decrease over earnings of $0.19 per share
Benzinga Newsdesk
American Express, Eni On Deck Friday As Spending, Energy Demand Face Test
American Express headlines Friday’s reports, with premium-card spending and consumer resilience the central questions after a sharp year-to-date stock decline. Eni SpA, SLB, Infosys, First Citizens BancShares, Rogers
Benzinga Insights
Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat
Dr. Reddy's (RDY) stock drops after missing Q1 FY27 earnings & revenue estimates. Semaglutide issues & Trump tariff plans weigh on shares.
Vandana Singh
PRO
Dr Reddy's Laboratories Q1 EPS $0.06 Misses $0.17 Estimate, Sales $853.000M Miss $925.530M Estimate
Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.17 by 64.71 percent. This is a 70 percent decrease over earnings of $0.20 per share
Benzinga Newsdesk
Earnings Scheduled For July 22, 2026
Companies Reporting Before The Bell • Northern Trust (NASDAQ:NTRS) is expected to report quarterly earnings at $3.45 per share on revenue of $2.35 billion. • Old National Bancorp (NASDAQ:ONB) is projected to report
Benzinga Insights
PRO
Dr Reddy's Laboratories Q4 EPS $0.03 Misses $0.09 Estimate, Sales $821.821M Miss $866.120M Estimate
Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.09 by 66.67 percent. This is a 86.36 percent decrease over earnings of $0.22 per share
Benzinga Newsdesk